Described herein are methods for treating rheumatoid arthritis by determining whether a subject having rheumatoid arthritis will respond to an anti-TNF-alpha therapy based on the number of innate and adaptive immune cells in a sample from the subject prior to treatment.

This invention provides methods to evaluate therapeutic efficacy of therapeutic monoclonal antibodies.

A method for visualizing multi-antigen binding capabilities of a set of clonotype groups. Clonotype data that identifies a clonotype group derived from an immune cell sequence dataset (e.g., single cell or spatial dataset) is obtained. A set of interactions for the clonotype group is identified. An interaction in the set of interactions is between a set of cells in the clonotype group and a plurality of antigens in which each cell of the set of cells binds to the plurality of antigens. A binding diagram is generated for the clonotype group based on the set of interactions that has been identified. The binding diagram includes a set of interaction representations that visually represents the set of interactions for the clonotype group. An interaction representation in the set of interaction representations visually relates the plurality of antigens and visually indicates a number of cells in the set of cells that bind to the plurality of antigens.

[Problem]

To find a method having higher stability, reproducibility, economic efficiency, and operation easiness in an evaluation method of safety of a substance in vitro, by using human immortalized myeloid cells.

[Solving Means]

A method for evaluating the skin sensitizing property and/or the pyrogenic property of a test substance, a method for detecting a skin sensitizer and/or a pyrogen in a sample, and a method for evaluating the action of a sample on a function of immune cells, each using human immortalized myeloid cells and including measuring the production amount of IL-6 and/or IL-8 in a culture medium of human immortalized myeloid cells.

Provided are a composition and method for inducing direct conversion from a somatic cell into a myeloid cell and use thereof, in which differentiation from a somatic cell into a myeloid cell can be efficiently induced through the expression of a single direct conversion inducer without undergoing the pluripotency stage of induced pluripotent stem cells, and thus, the composition can be widely used as an effective preventive and therapeutic agent for immune diseases.

A microfluidic system for measuring cell adhesion includes a gas impermeable housing including at least one microchannel defining at least one cell adhesion region, the at least one cell adhesion region being provided with at least one capturing agent that adheres a cell of interest to a surface of the at least one microchannel when a fluid sample containing cells is passed through the at least one microchannel, and an imaging system for measuring the adherence of cells of interest adhered by the at least one capturing agent to the surface of the at least one microchannel when the fluid sample is passed therethrough.

The present description relates to the use of a SRSF3 agent for regulating the function of a myeloid cell, such as a microglial cell and/or monocyte, for treating neurological conditions, cancers, bacterial infections and viral infections wherein the SRSF3 agent inhibits expression or function of SRSF3.

The present invention provides isolated immune cells, immune cell populations and compositions, as well as markers, marker signatures and molecular targets characterising the immune cells. The cell products, substances, compositions, markers, marker signatures, molecular targets, kits of parts and methods of the present invention provide for new ways to characterise, evaluate and modulate the immune system and immune responses.

The present invention relates to the field of ophthalmology. More specifically, the present invention provides compositions and methods useful for screening for drugs to treat age-related macular degeneration (AMD) including geographic atrophy (GA). In one embodiment, a method comprises the steps of (a) administering a drug to a mammal, wherein the mammal comprises a rat or a mouse; (b) enucleating the eyes of the mammal; (c) removing the anterior eye and excising the retina from the eye, wherein the eye comprises an eyecup that comprises choroidal mast cells (MCs); and (d) measuring mast cell degranulation. In an alternative embodiment, a method of the present invention can comprise the steps of (a) contacting an eyecup of a mammal with a drug, wherein the eyecup comprises choroidal mast cells; and (b) measuring MC degranulation.

The present invention provides compositions, systems, kits, and methods for analyzing the interaction of T-cells and neoantigen presenting cells (and other cells) via discrete entity (e.g., droplet) microfluids. In certain embodiments, a microfluidic device is used to merge a discrete entity containing a T-cell, and a discrete entity containing a neoantigen presenting cell, at a merger region via a trapping element in order to generate a combined discrete entity. In particular embodiments, at least one thousand of such combined discrete entities are formed in about one second. In some embodiments, whether the receptor on the T-cell sufficiently binds the neoantigen to activate the T-Cell is detected (e.g., via detection of cytokine or granzyme B release). In certain embodiments, provided herein are methods for identifying polyfunctional T-cells or NK-cells, as well as methods of screening for such cells that would be cytotoxic if injected into a subject.